CORE LAB REPORTS THIRD QUARTER 2025 RESULTS
Rhea-AI Summary
Core Laboratories (NYSE: CLB) reported Q3 2025 revenue of $134.5M, GAAP operating income of $20.9M and GAAP EPS of $0.30. Operating income, ex-items, was $16.6M and EPS, ex-items, was $0.22. The company generated $6.5M free cash flow, repurchased 462,248 shares for $5.0M (≈1% of outstanding shares), and reduced net debt by $3.4M to $91.4M, lowering leverage to 1.10. On Oct 1, 2025 Core completed the acquisition of Brazil-based Solintec for an initial cash payment of $2.3M plus an earnout up to $3.7M. Q4 2025 guidance: revenue $132M–$136M, operating income $14M–$16.1M, EPS $0.18–$0.22. The Board approved a quarterly cash dividend of $0.01 per share.
Positive
- Revenue of $134.5M in Q3 2025
- Operating income, ex-items, of $16.6M
- Free cash flow of $6.5M in Q3 2025
- Share repurchases: 462,248 shares for $5.0M
- Net debt reduced by $3.4M to $91.4M; leverage improved to 1.10
- Completed Solintec acquisition: $2.3M initial cash, earnout up to $3.7M
Negative
- EPS, ex-items, down 12% YoY
- Operating income essentially flat year-over-year
- Production Enhancement projected to be down slightly in Q4 2025 due to U.S. onshore seasonality
- Tariff headwinds and OPEC+ production changes cited as near-term market risks
News Market Reaction 51 Alerts
On the day this news was published, CLB gained 6.06%, reflecting a notable positive market reaction. Argus tracked a peak move of +35.3% during that session. Our momentum scanner triggered 51 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $45M to the company's valuation, bringing the market cap to $795M at that time. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
-
REVENUE OF
, UP OVER$134.5 MILLION 3% SEQUENTIALLY AND FLAT YEAR-OVER-YEAR -
OPERATING INCOME OF
; EX-ITEMS,$20.9 MILLION , UP OVER$16.6 MILLION 14% SEQUENTIALLY AND DOWN9% YEAR-OVER-YEAR -
OPERATING MARGINS, EX-ITEMS, OF OVER
12% , EXPANDED 120 BASIS POINTS SEQUENTIALLY, WITH INCREMENTAL MARGINS, EX-ITEMS, OF48% -
GAAP EPS OF
$0.30 ; EX-ITEMS, , UP$0.22 16% SEQUENTIALLY, AND DOWN12% YEAR-OVER-YEAR -
COMPANY REPURCHASED 462,248 SHARES OF COMMON STOCK, A VALUE OF
MILLION$5.0 -
FREE CASH FLOW OF
$6.5 MILLION -
NET DEBT REDUCED BY
; LEVERAGE RATIO IMPROVED TO 1.10$3.4 MILLION - COMPANY ANNOUNCES Q3 2025 QUARTERLY DIVIDEND
Core's CEO, Larry Bruno, stated, "Core Lab delivered another quarter of sequential revenue growth, driven by global demand for our proprietary services and products, along with sequential improvement in operating income, operating margins, and earnings per share. During the third quarter, face-to-face meetings with clients throughout the
Reservoir Description
Reservoir Description operations are closely correlated with trends in international and offshore activity levels, with approximately
During the third quarter of 2025, Core Lab advanced its position as the leader in integrated geological and reservoir analyses with the delivery of multi-client studies in two key offshore exploration areas,
On October 1, 2025, Core Lab completed the acquisition of
Production Enhancement
Production Enhancement operations, which are focused on complex completions in unconventional oil and gas reservoirs in the
In the third quarter of 2025, a major international operator in
Also in the third quarter, Core Lab was engaged by a National Oil Company in the
Liquidity, Free Cash Flow, Share Repurchases, and Dividend
Core continues to focus on maximizing free cash flow ("FCF"), a non-GAAP financial measure defined as cash from operations less capital expenditures. For the third quarter of 2025, cash from operations was
In the third quarter of 2025, Core Lab used a portion of its FCF to repurchase 462,248 shares at an aggregate purchase price of
As of September 30, 2025, Core's net debt (defined as long-term debt less cash and cash equivalents) was
On July 23, 2025, Core's Board of Directors ("Board") announced a quarterly cash dividend of
On October 22, 2025, the Board approved a cash dividend of
Return On Invested Capital
The Board and the Company's Executive Management continue to focus on strategies that maximize return on invested capital ("ROIC") and FCF, factors that have high correlation to total shareholder return. Core's commitment to an asset-light business model and disciplined capital stewardship promotes capital efficiency and are designed to produce more predictable and superior long-term ROIC.
The Board has established an internal metric to demonstrate ROIC performance relative to the oilfield service companies listed as Core's Comp Group by Bloomberg, as the Company continues to believe superior ROIC will result in higher total shareholder return. Using Bloomberg's formula, the Company's ROIC for the third quarter of 2025 improved to
Industry and Core Lab Outlook and Guidance
The IEA, EIA, and OPEC+ continue to forecast growth in crude oil demand to be between 0.7 and 1.3 million barrels per day in 2025, with a similar level of incremental growth projected for 2026. This demand is primarily driven by non-OECD countries in
As noted in the IEA's report published on September 16, 2025, crude oil field data shows the natural decline in existing producing fields is accelerating globally and now represents a major long term supply risk. Addressing steeper decline rates and bringing new fields online will be central to ensuring energy security and maintaining market stability. As such, according to the IEA, significant annual investment in oil and gas resource development will be required for many years to come. Core Lab's Reservoir Description and Production Enhancement technologies are directly aligned with these investment imperatives.
In the near term, potential tariff headwinds combined with OPEC+ decisions to increase production levels, are contributing to market volatility and lower commodity prices. Despite the current softness, longer-term crude oil demand fundamentals remain intact. Core Lab maintains its constructive multi-year outlook, and continues to see steady activity across committed long-cycle projects, including deepwater, along the South Atlantic Margin, North and
Activity levels tied to smaller-scale, short-cycle crude oil development projects are expected to remain more sensitive to changes in commodity prices. As a result, changes in crude oil prices are anticipated to have a more immediate impact on drilling and completion activity in the
Geopolitical conflicts, evolving trade and tariff dynamics, and volatile commodity prices continue to create uncertainty in the demand for laboratory services tied to the maritime transportation and trade of crude oil and derived products. Despite these headwinds, Core projects Reservoir Description's fourth quarter revenue to be up sequentially. The
Core Lab believes that the tariff measures under consideration will not apply to the vast majority of service revenue and product sales provided by the Company. Core's services account for over
Reservoir Description's fourth quarter revenue is projected to range from
Core's fourth quarter 2025 revenue is projected to range from
The Company's fourth quarter 2025 guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange. Fourth quarter guidance assumes an effective tax rate of
Earnings Call Scheduled
The Company has scheduled a conference call to discuss Core's third quarter 2025 earnings announcement. The call will begin at 7:30 a.m. CDT / 8:30 a.m. EDT on Thursday, October 23, 2025. To log on to the listen-only webcast, visit www.corelab.com/investors 15 minutes before the start of the call. For those not available to listen to the live webcast, a replay and transcript will be available on the Company's website shortly after the call. Analysts may contact investor.relations@corelab.com for conference call dial-in information.
Core Laboratories Inc. is a leading provider of proprietary and patented reservoir description and production enhancement services and products used to optimize petroleum reservoir performance. The Company has over 70 offices in more than 50 countries and is located in every major oil-producing province in the world. This release, as well as other statements Core Lab makes, includes forward-looking statements regarding the Company's future revenue, profitability, business strategies and developments, demand for the Company's products and services and for products and services of the oil and gas industry generally, made in reliance upon the safe harbor provisions of Federal securities law. The Company's outlook is subject to various important cautionary factors, including risks and uncertainties related to the oil and natural gas industry, business and general economic conditions, including inflationary pressures, the impact on tariffs and sanctions, international markets, international political climates, including the
The Company undertakes no obligation to publicly update or revise any forward-looking statement to reflect events or circumstances that may arise after the date of this press release, except as required by law.
Visit the Company's website at www.corelab.com.
|
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) (Unaudited) |
||||||||||||||||
|
|
||||||||||||||||
|
|
|
Three Months Ended |
|
|
% Variance |
|||||||||||
|
|
|
September 30, |
|
|
June 30, |
|
|
September 30, |
|
|
vs. Q2-25 |
|
vs. Q3-24 |
|||
|
REVENUE |
|
$ |
134,521 |
|
|
$ |
130,159 |
|
|
$ |
134,397 |
|
|
3.4 % |
|
0.1 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
OPERATING EXPENSES: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Costs of services and product sales |
|
|
104,901 |
|
|
|
103,701 |
|
|
|
106,805 |
|
|
1.2 % |
|
(1.8) % |
|
General and administrative |
|
|
10,688 |
|
|
|
10,464 |
|
|
|
8,642 |
|
|
2.1 % |
|
23.7 % |
|
Depreciation and amortization |
|
|
3,594 |
|
|
|
3,670 |
|
|
|
3,676 |
|
|
(2.1) % |
|
(2.2) % |
|
Other (income) expense, net |
|
|
(5,590) |
|
|
|
(2,967) |
|
|
|
(4,529) |
|
|
NM |
|
NM |
|
Total operating expenses |
|
|
113,593 |
|
|
|
114,868 |
|
|
|
114,594 |
|
|
(1.1) % |
|
(0.9) % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
OPERATING INCOME |
|
|
20,928 |
|
|
|
15,291 |
|
|
|
19,803 |
|
|
36.9 % |
|
5.7 % |
|
Interest expense |
|
|
2,650 |
|
|
|
2,711 |
|
|
|
3,108 |
|
|
(2.3) % |
|
(14.7) % |
|
Income before income taxes |
|
|
18,278 |
|
|
|
12,580 |
|
|
|
16,695 |
|
|
45.3 % |
|
9.5 % |
|
Income tax expense |
|
|
3,754 |
|
|
|
1,911 |
|
|
|
4,691 |
|
|
96.4 % |
|
(20.0) % |
|
Net income |
|
|
14,524 |
|
|
|
10,669 |
|
|
|
12,004 |
|
|
NM |
|
21.0 % |
|
Net income attributable to non- |
|
|
285 |
|
|
|
33 |
|
|
|
259 |
|
|
NM |
|
NM |
|
Net income attributable to Core |
|
$ |
14,239 |
|
|
$ |
10,636 |
|
|
$ |
11,745 |
|
|
33.9 % |
|
21.2 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Diluted earnings per share |
|
$ |
0.31 |
|
|
$ |
0.23 |
|
|
$ |
0.25 |
|
|
34.8 % |
|
24.0 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Diluted earnings per share |
|
$ |
0.30 |
|
|
$ |
0.22 |
|
|
$ |
0.25 |
|
|
36.4 % |
|
20.0 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Diluted weighted average common |
|
|
47,078 |
|
|
|
47,364 |
|
|
|
47,820 |
|
|
(0.6) % |
|
(1.6) % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Effective tax rate |
|
|
21 |
% |
|
|
15 |
% |
|
|
28 |
% |
|
NM |
|
NM |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
SEGMENT INFORMATION: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Reservoir Description |
|
$ |
88,224 |
|
|
$ |
86,280 |
|
|
$ |
88,840 |
|
|
2.3 % |
|
(0.7) % |
|
Production Enhancement |
|
|
46,297 |
|
|
|
43,879 |
|
|
|
45,557 |
|
|
5.5 % |
|
1.6 % |
|
Consolidated |
|
$ |
134,521 |
|
|
$ |
130,159 |
|
|
$ |
134,397 |
|
|
3.4 % |
|
0.1 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Operating income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Reservoir Description |
|
$ |
16,574 |
|
|
$ |
12,203 |
|
|
$ |
16,487 |
|
|
35.8 % |
|
0.5 % |
|
Production Enhancement |
|
|
4,379 |
|
|
|
3,148 |
|
|
|
3,232 |
|
|
39.1 % |
|
35.5 % |
|
Corporate and Other |
|
|
(25) |
|
|
|
(60) |
|
|
|
84 |
|
|
NM |
|
NM |
|
Consolidated |
|
$ |
20,928 |
|
|
$ |
15,291 |
|
|
$ |
19,803 |
|
|
36.9 % |
|
5.7 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
"NM" means not meaningful |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) (Unaudited) |
||||||||||
|
|
|
|
|
|
|
|||||
|
|
|
Nine Months Ended |
|
|
% Variance |
|||||
|
|
|
2025 |
|
|
2024 |
|
|
|
||
|
REVENUE |
|
$ |
388,265 |
|
|
$ |
394,611 |
|
|
(1.6) % |
|
|
|
|
|
|
|
|
|
|
||
|
OPERATING EXPENSES: |
|
|
|
|
|
|
|
|
||
|
Costs of services and product sales |
|
|
308,071 |
|
|
|
314,323 |
|
|
(2.0) % |
|
General and administrative expense |
|
|
34,799 |
|
|
|
30,690 |
|
|
13.4 % |
|
Depreciation and amortization |
|
|
10,981 |
|
|
|
11,289 |
|
|
(2.7) % |
|
Other (income) expense, net |
|
|
(6,222) |
|
|
|
(6,073) |
|
|
NM |
|
Total operating expenses |
|
|
347,629 |
|
|
|
350,229 |
|
|
(0.7) % |
|
|
|
|
|
|
|
|
|
|
||
|
OPERATING INCOME |
|
|
40,636 |
|
|
|
44,382 |
|
|
(8.4) % |
|
Interest expense |
|
|
7,963 |
|
|
|
9,740 |
|
|
(18.2) % |
|
Income before income taxes |
|
|
32,673 |
|
|
|
34,642 |
|
|
(5.7) % |
|
Income tax expense |
|
|
7,411 |
|
|
|
9,958 |
|
|
(25.6) % |
|
Net income |
|
|
25,262 |
|
|
|
24,684 |
|
|
2.3 % |
|
Net income attributable to non-controlling interest |
|
|
541 |
|
|
|
687 |
|
|
NM |
|
Net income attributable to Core Laboratories Inc. |
|
$ |
24,721 |
|
|
$ |
23,997 |
|
|
3.0 % |
|
|
|
|
|
|
|
|
|
|
||
|
Diluted earnings per share |
|
$ |
0.53 |
|
|
$ |
0.52 |
|
|
1.9 % |
|
|
|
|
|
|
|
|
|
|
||
|
Diluted earnings per share attributable to Core Laboratories Inc. |
|
$ |
0.52 |
|
|
$ |
0.50 |
|
|
4.0 % |
|
|
|
|
|
|
|
|
|
|
||
|
Diluted weighted average common shares outstanding |
|
|
47,381 |
|
|
|
47,690 |
|
|
(0.6) % |
|
|
|
|
|
|
|
|
|
|
||
|
Effective tax rate |
|
|
23 |
% |
|
|
29 |
% |
|
NM |
|
|
|
|
|
|
|
|
|
|
||
|
SEGMENT INFORMATION: |
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||
|
Revenue: |
|
|
|
|
|
|
|
|
||
|
Reservoir Description |
|
$ |
255,401 |
|
|
$ |
259,353 |
|
|
(1.5) % |
|
Production Enhancement |
|
|
132,864 |
|
|
|
135,258 |
|
|
(1.8) % |
|
Total |
|
$ |
388,265 |
|
|
$ |
394,611 |
|
|
(1.6) % |
|
|
|
|
|
|
|
|
|
|
||
|
Operating income: |
|
|
|
|
|
|
|
|
||
|
Reservoir Description |
|
$ |
31,116 |
|
|
$ |
34,823 |
|
|
(10.6) % |
|
Production Enhancement |
|
|
9,030 |
|
|
|
9,209 |
|
|
(1.9) % |
|
Corporate and Other |
|
|
490 |
|
|
|
350 |
|
|
NM |
|
Total |
|
$ |
40,636 |
|
|
$ |
44,382 |
|
|
(8.4) % |
|
|
|
|
|
|
|
|
|
|
||
|
"NM" means not meaningful |
|
|
|
|
|
|
|
|
||
|
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited) |
||||||||||||||||
|
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
% Variance |
|||||
|
ASSETS: |
|
September 30, |
|
|
June 30, |
|
|
December 31, |
|
|
vs. Q2-25 |
|
vs. Q4-24 |
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Cash and cash equivalents |
|
$ |
25,629 |
|
|
$ |
31,188 |
|
|
$ |
19,157 |
|
|
(17.8) % |
|
33.8 % |
|
Accounts receivable, net |
|
|
110,258 |
|
|
|
113,909 |
|
|
|
111,761 |
|
|
(3.2) % |
|
(1.3) % |
|
Inventories |
|
|
58,241 |
|
|
|
59,773 |
|
|
|
59,402 |
|
|
(2.6) % |
|
(2.0) % |
|
Other current assets |
|
|
32,786 |
|
|
|
32,807 |
|
|
|
36,286 |
|
|
(0.1) % |
|
(9.6) % |
|
Total current assets |
|
|
226,914 |
|
|
|
237,677 |
|
|
|
226,606 |
|
|
(4.5) % |
|
0.1 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Property, plant and equipment, net |
|
|
98,031 |
|
|
|
97,927 |
|
|
|
97,063 |
|
|
0.1 % |
|
1.0 % |
|
Right of use assets |
|
|
53,980 |
|
|
|
55,116 |
|
|
|
56,488 |
|
|
(2.1) % |
|
(4.4) % |
|
Intangibles, goodwill and other long- |
|
|
212,435 |
|
|
|
211,391 |
|
|
|
210,249 |
|
|
0.5 % |
|
1.0 % |
|
Total assets |
|
$ |
591,360 |
|
|
$ |
602,111 |
|
|
$ |
590,406 |
|
|
(1.8) % |
|
0.2 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
LIABILITIES AND EQUITY: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Accounts payable |
|
$ |
36,945 |
|
|
$ |
41,699 |
|
|
$ |
34,549 |
|
|
(11.4) % |
|
6.9 % |
|
Short-term operating lease liabilities |
|
|
11,474 |
|
|
|
11,508 |
|
|
|
10,690 |
|
|
(0.3) % |
|
7.3 % |
|
Other current liabilities |
|
|
47,324 |
|
|
|
51,565 |
|
|
|
52,347 |
|
|
(8.2) % |
|
(9.6) % |
|
Total current liabilities |
|
|
95,743 |
|
|
|
104,772 |
|
|
|
97,586 |
|
|
(8.6) % |
|
(1.9) % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Long-term debt, net |
|
|
114,103 |
|
|
|
124,613 |
|
|
|
126,111 |
|
|
(8.4) % |
|
(9.5) % |
|
Long-term operating lease liabilities |
|
|
41,525 |
|
|
|
42,420 |
|
|
|
43,343 |
|
|
(2.1) % |
|
(4.2) % |
|
Other long-term liabilities |
|
|
62,601 |
|
|
|
63,003 |
|
|
|
65,630 |
|
|
(0.6) % |
|
(4.6) % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Total equity |
|
|
277,388 |
|
|
|
267,303 |
|
|
|
257,736 |
|
|
3.8 % |
|
7.6 % |
|
Total liabilities and equity |
|
$ |
591,360 |
|
|
$ |
602,111 |
|
|
$ |
590,406 |
|
|
(1.8) % |
|
0.2 % |
|
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) |
||||||||
|
|
||||||||
|
|
|
Nine Months Ended September 30, |
|
|||||
|
|
|
2025 |
|
|
2024 |
|
||
|
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
|
|
|
|
||
|
Net income |
|
$ |
25,262 |
|
|
$ |
24,684 |
|
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
||
|
Stock-based compensation |
|
|
6,023 |
|
|
|
4,213 |
|
|
Depreciation and amortization |
|
|
10,981 |
|
|
|
11,289 |
|
|
Deferred income taxes |
|
|
(4,573) |
|
|
|
102 |
|
|
Insurance recovery on property, plant and equipment |
|
|
(6,830) |
|
|
|
(2,102) |
|
|
Accounts receivable |
|
|
(615) |
|
|
|
(9,461) |
|
|
Inventories |
|
|
(1,268) |
|
|
|
5,197 |
|
|
Accounts payable |
|
|
1,284 |
|
|
|
(373) |
|
|
Other adjustments to net income |
|
|
(1,179) |
|
|
|
2,224 |
|
|
Net cash provided by operating activities |
|
|
29,085 |
|
|
|
35,773 |
|
|
|
|
|
|
|
|
|
||
|
CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
|
|
|
|
||
|
Capital expenditures - operations |
|
|
(8,265) |
|
|
|
(8,647) |
|
|
Capital expenditures - rebuilding of |
|
|
(2,672) |
|
|
|
— |
|
|
Net proceeds from insurance recovery - |
|
|
9,951 |
|
|
|
2,102 |
|
|
Net proceeds on life insurance policies |
|
|
778 |
|
|
|
2,776 |
|
|
Other investing activities |
|
|
1,729 |
|
|
|
934 |
|
|
Net cash provided by (used in) investing activities |
|
|
1,521 |
|
|
|
(2,835) |
|
|
|
|
|
|
|
|
|
||
|
CASH FLOWS FROM FINANCING ACTIVITIES: |
|
|
|
|
|
|
||
|
Repayment of long-term debt |
|
|
(47,000) |
|
|
|
(62,000) |
|
|
Proceeds from long-term debt |
|
|
36,000 |
|
|
|
38,000 |
|
|
Debt issuance costs |
|
|
(1,706) |
|
|
|
— |
|
|
Dividends paid |
|
|
(1,403) |
|
|
|
(1,407) |
|
|
Repurchase of common stock |
|
|
(9,770) |
|
|
|
(402) |
|
|
Other financing activities |
|
|
(255) |
|
|
|
(775) |
|
|
Net cash used in financing activities |
|
|
(24,134) |
|
|
|
(26,584) |
|
|
|
|
|
|
|
|
|
||
|
NET CHANGE IN CASH AND CASH EQUIVALENTS |
|
|
6,472 |
|
|
|
6,354 |
|
|
CASH AND CASH EQUIVALENTS, beginning of period |
|
|
19,157 |
|
|
|
15,120 |
|
|
CASH AND CASH EQUIVALENTS, end of period |
|
$ |
25,629 |
|
|
$ |
21,474 |
|
Non-GAAP Information
Management believes that the exclusion of certain income and expenses enables it to evaluate more effectively the Company's operations period-over-period and to identify operating trends that could otherwise be masked by the excluded Items. For this reason, management uses certain non-GAAP measures that exclude these Items and believes that this presentation provides a clearer comparison with the results reported in prior periods. The non-GAAP financial measures should be considered in addition to, and not as a substitute for, the financial results prepared in accordance with GAAP, as more fully discussed in the Company's financial statements and filings with the Securities and Exchange Commission.
|
Reconciliation of Operating Income, Net Income and Diluted Earnings Per Share Attributable to (In thousands, except per share data) (Unaudited) |
||||||||||||
|
|
||||||||||||
|
|
|
Operating Income |
|
|||||||||
|
|
|
Three Months Ended |
|
|||||||||
|
|
|
September 30, |
|
|
June 30, |
|
|
September 30, |
|
|||
|
GAAP reported |
|
$ |
20,928 |
|
|
$ |
15,291 |
|
|
$ |
19,803 |
|
|
Stock compensation (1) |
|
|
— |
|
|
|
— |
|
|
|
(1,364) |
|
|
Asset write-downs (2) |
|
|
601 |
|
|
|
799 |
|
|
|
— |
|
|
Insurance recovery on property, plant and equipment (3) |
|
|
(5,252) |
|
|
|
(1,557) |
|
|
|
— |
|
|
Foreign exchange losses (gains) |
|
|
354 |
|
|
|
7 |
|
|
|
(239) |
|
|
Excluding specific items |
|
$ |
16,631 |
|
|
$ |
14,540 |
|
|
$ |
18,200 |
|
|
|
|
Net Income Attributable to Core Laboratories Inc. |
|
|||||||||
|
|
|
Three Months Ended |
|
|||||||||
|
|
|
September 30, |
|
|
June 30, |
|
|
September 30, |
|
|||
|
GAAP reported |
|
$ |
14,239 |
|
|
$ |
10,636 |
|
|
$ |
11,745 |
|
|
Stock compensation (1) |
|
|
— |
|
|
|
— |
|
|
|
(1,091) |
|
|
Asset write-downs (2) |
|
|
451 |
|
|
|
599 |
|
|
|
— |
|
|
Insurance recovery on property, plant and equipment (3) |
|
|
(3,939) |
|
|
|
(1,168) |
|
|
|
— |
|
|
Foreign exchange losses (gains) |
|
|
265 |
|
|
|
5 |
|
|
|
(191) |
|
|
Effect of higher (lower) tax rate (4) |
|
|
(815) |
|
|
|
(1,234) |
|
|
|
1,351 |
|
|
Excluding specific items |
|
$ |
10,201 |
|
|
$ |
8,838 |
|
|
$ |
11,814 |
|
|
|
|
Diluted Earnings Per Share Attributable to Core Laboratories |
|
|||||||||
|
|
|
Three Months Ended |
|
|||||||||
|
|
|
September 30, |
|
|
June 30, |
|
|
September 30, |
|
|||
|
GAAP reported |
|
$ |
0.30 |
|
|
$ |
0.22 |
|
|
$ |
0.25 |
|
|
Stock compensation (1) |
|
|
— |
|
|
|
— |
|
|
|
(0.02) |
|
|
Asset write-downs (2) |
|
|
0.01 |
|
|
|
0.01 |
|
|
|
— |
|
|
Insurance recovery on property, plant and equipment (3) |
|
|
(0.08) |
|
|
|
(0.02) |
|
|
|
— |
|
|
Foreign exchange losses (gains) |
|
|
0.01 |
|
|
|
— |
|
|
|
(0.01) |
|
|
Effect of higher (lower) tax rate (4) |
|
|
(0.02) |
|
|
|
(0.02) |
|
|
|
0.03 |
|
|
Excluding specific items |
|
$ |
0.22 |
|
|
$ |
0.19 |
|
|
$ |
0.25 |
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
(1) Three months ended September 30, 2024 includes reversals of stock compensation expense previously recognized due to change in |
|
|||||||||||
|
(2) Three months ended June 30, 2025 and September 30, 2025 includes the write-down of inventory. |
|
|||||||||||
|
(3) Three months ended June 30, 2025 and September 30, 2025 includes an insurance recovery associated with the fire at the |
|
|||||||||||
|
(4) Three months ended September 30, 2024 reflects tax expense at a normalized rate of |
|
|||||||||||
|
Segment Information (In thousands) (Unaudited) |
||||||||||||
|
|
||||||||||||
|
|
|
Operating Income |
|
|||||||||
|
|
|
Three Months Ended September 30, 2025 |
|
|||||||||
|
|
|
Reservoir |
|
|
Production |
|
|
Corporate and |
|
|||
|
GAAP reported |
|
$ |
16,574 |
|
|
$ |
4,379 |
|
|
$ |
(25) |
|
|
Asset write-downs |
|
|
— |
|
|
|
601 |
|
|
|
— |
|
|
Insurance recovery on property, plant and equipment |
|
|
(5,252) |
|
|
|
— |
|
|
|
— |
|
|
Foreign exchange losses (gains) |
|
|
311 |
|
|
|
(76) |
|
|
|
119 |
|
|
Excluding specific items |
|
$ |
11,633 |
|
|
$ |
4,904 |
|
|
$ |
94 |
|
Return on Invested Capital
Return on Invested Capital ("ROIC") is presented based on management's belief that this non-GAAP measure is useful information to investors and management when comparing profitability and the efficiency with which capital has been employed over time relative to other companies. The Board has established an internal metric to demonstrate ROIC performance relative to the oilfield service companies listed as Core's Comp Group by Bloomberg. ROIC is not a measure of financial performance under GAAP and should not be considered as an alternative to net income.
ROIC of
Free Cash Flow
Core uses the non-GAAP financial measure of free cash flow to evaluate its cash flows and results of operations. Free cash flow is defined as net cash provided by operating activities (which is the most directly comparable GAAP measure) less cash paid for capital expenditures - operations. Management believes that free cash flow provides useful information to investors regarding the cash available in the period in excess of Core's needs to fund its capital expenditures and operating activities. Free cash flow is not a measure of operating performance under GAAP and should not be considered in isolation nor construed as an alternative to operating income, net income, or cash flows from operating, investing, or financing activities, each as determined in accordance with GAAP. Free cash does not represent residual cash available for distribution because Core may have other non-discretionary expenditures that are not deducted from the measure. Moreover, since free cash flow is not a measure determined in accordance with GAAP and thus is susceptible to varying interpretations and calculations, free cash flow as presented may not be comparable to similarly titled measures presented by other companies.
|
Computation of Free Cash Flow (In thousands) (Unaudited) |
|||||||||
|
|
|||||||||
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
|
||
|
|
|
September 30, 2025 |
|
|
September 30, 2025 |
|
|
||
|
Net cash provided by operating activities |
|
$ |
8,502 |
|
|
$ |
29,085 |
|
|
|
Capital expenditures - operations |
|
|
(2,006) |
|
|
|
(8,265) |
|
|
|
Free cash flow |
|
$ |
6,496 |
|
|
$ |
20,820 |
|
|
View original content to download multimedia:https://www.prnewswire.com/news-releases/core-lab-reports-third-quarter-2025-results-302591961.html
SOURCE Core Laboratories Inc